Print

Print


The source of this article is Newswise: http://tinyurl.com/4rq7e

Parkinson’s Disease: Shootout at the Microtubule Corral?

Parkinson’s is caused by the selective death of dopamine-producing neurons. 
By using an agricultural pesticide known to produce “Parkinson-like” 
symptoms, a researcher has found connections between pesticide damage and 
mutated parkin.

Newswise — Parkinson’s disease (PD) was named for English physician James 
Parkinson, who in 1817 first described the “shaking palsy” now recognized as 
a progressive neurodegenerative disease. Parkinson’s is caused by the 
selective death of neurons that produce dopamine, a chemical required by 
brain circuits that control body movement. Parkinson’s affects about 500,000 
mostly older Americans, with 50,000 new cases diagnosed each year. Familial 
and young-onset cases of PD are linked to mutations in “parkin,” a gene on 
chromosome 6. The parkin protein is a type of enzyme known as an E3 
ubiquitin ligase, which targets (‘tags’) specific proteins for degradation 
within cells. 

Mutations in parkin (and other less-understood genes) clearly create a 
“predisposition” for PD. However the question of what actually triggers 
pathology in dopamine-producing neurons is highly controversial, and may 
hinge on a delicate balance between genetics, environmental insults, 
oxidative stress and cell aging. For example, the agricultural pesticide 
rotenone can produce “Parkinson-like” symptoms in laboratory animals, but 
rotenone exposure is clearly not the sole cause of PD in humans. Jian Feng, 
a researcher at the State University of New York at Buffalo, wondered if the 
damage caused by rotenone might somehow involve parkin. 

To understand how rotenone kills dopamine-producing cells, Feng’s lab first 
treated neuronal cultures from embryonic rat brains with the drug. 
Interestingly, rotenone selectively destroyed only dopamine-producing 
neurons, and spared other types of neurons. Rotenone has two known targets 
in cells: mitochondria (the cell’s ‘power plants’) and microtubules, which 
are highways for intracellular transport. Rotenone inhibits mitochondrial 
complex I, resulting in a cascade of highly-toxic free radicals. By 
depolymerizing microtubules, rotenone halts the movement of intracellular 
transport vesicles, including dopamine-containing vesicles, which then leak 
their contents into the cytosol. The spilled dopamine oxides generate even 
more free radicals. Free radicals can damage tubulin, the protein building 
blocks of microtubules. In neurons that do not produce dopamine, the 
chemicals transported along microtubules are not toxic. Thus, the selective 
vulnerability of dopamine-producing neurons to rotenone seems to lie in the 
vulnerability of their microtubule highways and the toxicity of their unique 
dopamine cargo. Further supporting this idea, the microtubule-stabilizing 
drug taxol substantially protects neurons against rotenone toxicity. 

How does parkin fit this picture? Feng’s group found that parkin helps 
destroy unpolymerized tubulin. They speculate that this activity is normally 
beneficial, because it helps dispose of free radical-damaged tubulin. 
Supporting this idea, when Feng and colleagues over-expressed normal parkin, 
it protected dopamine-producing neurons against rotenone. In contrast, 
parkin mutants that had lost their enzymatic activity, and were unable to 
‘tag’ tubulin for destruction, failed to protect cells from rotenone. Thus, 
it appears that the survival of dopamine-producing neurons requires constant 
vigilance by parkin, which helps ‘keep the tracks clear’ by getting rid of 
damaged tubulin. This role, and neuronal survival, is challenged by 
rotenone, a prominent environmental factor linked to PD, which raises the 
levels of both unpolymerized and free-radical-damaged tubulin. In this 
fight, mutated parkin apparently arrives unarmed.

Rotenone and Parkin Act Antagonistically on Microtubules to Affect the 
Survival of Dopaminergic Neurons, Y. Ren, W. Liu, H. Jiang, J. Feng; 
Physiology and Biophysics, State University of New York at Buffalo, Buffalo, 
NY.

At the ASCB meeting: Poster Session 122, Nerve Cell Cytoskeleton, Halls D/E. 
Author presents: Sunday, Dec, 5, Noon —3:00 pm.

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn